Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of Cyanogramide to preparation of medicine for resisting mycobacterium tuberculosis

An anti-tuberculosis and drug technology, applied in antibacterial drugs and other directions, can solve the problems of non-standard treatment and management of tuberculosis patients, difficulties in tuberculosis prevention and control, etc. Effect

Inactive Publication Date: 2016-01-20
ZIBO DINGLI PATENT INFORMATION CONSULTING CO LTD
View PDF0 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, due to the irregular treatment and management of tuberculosis patients, irregular chemotherapy and abuse of anti-tuberculosis drugs, the drug resistance of tuberculosis is becoming more and more serious, and the change of drug resistance tends to be multi-drug resistance at the same time. great difficulty at work

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of Cyanogramide to preparation of medicine for resisting mycobacterium tuberculosis
  • Application of Cyanogramide to preparation of medicine for resisting mycobacterium tuberculosis
  • Application of Cyanogramide to preparation of medicine for resisting mycobacterium tuberculosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0016] Embodiment 1: the preparation of the compound Cyanogramide tablet involved in the present invention:

[0017] Take 20 grams of compound Cyanogramide, add 180 grams of conventional excipients for tablet preparation, mix well, and make 1000 tablets with a conventional tablet press.

Embodiment 2

[0018] Embodiment 2: the preparation of the compound Cyanogramide capsules involved in the present invention:

[0019] Get 20 grams of compound Cyanogramide, add conventional auxiliary materials such as starch 180 grams for preparing capsules, mix well, and pack into capsules to make 1000 capsules.

[0020] The following pharmacodynamic experiments will further illustrate its drug activity.

experiment example 1

[0021] Experimental Example 1 Solid Medium Dilution Method Determination of Cyanogramide Anti-Bacillus Calmette-Guerin (BCG) Absolute Concentration

[0022] Scrape the BCG culture from the inclined surface, add it to 3ml Middlebrook7H9 broth medium, add a small amount of glass beads, tighten the test tube cap, vibrate and grind vigorously on the vortex oscillator, and compare it with the standard McFarland turbidimetric tube (MacFarland No.1). Turbidity, that is to make 1mg / ml bacillus Calmette-Guerin (BCG) bacterial suspension. Cyanogramide is made into a high-concentration stock solution with DMSO, and the stock solution is diluted to the required concentration with 5% Tween-80 sterile ultrapure water, and the diluted Cyanogramide is added to 4ml Middlebrook7H11 agar medium according to the required dose (the culture base has been sterilized by high pressure steam at 121°C for 15 minutes, cooled to 50-55°C), mixed evenly, and made to contain Cyanogramide, the concentrations ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of Cyanogramide to preparation of medicine for resisting mycobacterium tuberculosis. Targeting the current situation that high morbidity of tuberculosis and appearance of mycobacterium tuberculosis multi-drug-resistant strains lead to a rising trend of the tuberculosis morbidity and the death rate, it is found that Cyanogramide has remarkable activity in inhibiting mycobacterium tuberculosis and then has a very good application prospect. The usage of Cyanogramide in preparing the medicine for treating and resisting mycobacterium tuberculosis is disclosed for the first time; due to the fact that the framework type is brand new and the activity of Cyanogramide in inhibiting mycobacterium tuberculosis is too strong to imagine, it is impossible to give any revelation by other compounds, and Cyanogramide has outstanding substantive characteristics; meanwhile, Cyanogramide apparently has remarkable progress when applied to prevention and treatment of mycobacterium tuberculosis infection.

Description

technical field [0001] The present invention relates to a new application of the compound Cyanogramide, in particular to the application of Cyanogramide in the preparation of anti-tuberculosis drugs. Background technique [0002] In recent years, the incidence of tuberculosis in the world has shown an increasing trend. According to the World Health Organization (WHO) estimates, the population infected by Mycobacterium tuberculosis (MTB) accounts for one-third of the world's population, and 5-10% of them are infected. become tuberculosis patients. There are 1.3 million cases of active tuberculosis patients in my country every year, including about 600,000 cases of infectious tuberculosis, and about 600,000 cases of infectious tuberculosis. It is one of the countries with a high burden of tuberculosis in the world. [0003] Since the advent of anti-tuberculosis drugs one after another, the treatment of tuberculosis has played an epoch-making change. However, due to the irreg...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/4188A61P31/06
Inventor 田丽华
Owner ZIBO DINGLI PATENT INFORMATION CONSULTING CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com